An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer

Until recently, effective therapies for advanced endometrial cancer progressing to a platinum-based combination were lacking. In this setting, immunotherapy with anti PD-1/PDL-1 monoclonal antibodies is rising as a new paradigm in particular for patients with microsatellites instability/mismatch rep...

Full description

Bibliographic Details
Main Authors: Michele Bartoletti, Giorgio Giorda, Alessandra Viel, Mara Fornasarig, Adrian Zdjelar, Enrica Segatto, Roberto Sorio, Serena Corsetti, Simona Scalone, Milena Sabrina Nicoloso, Tania Pivetta, Emilio Lucia, Nicolò Clemente, Elisa Palazzari, Vincenzo Canzonieri, Fabio Puglisi
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Current Oncology
Subjects:
endometrial cancer
dostarlimab
immunotherapy
predictive biomarkers
Online Access:https://www.mdpi.com/1718-7729/29/8/413

Internet

https://www.mdpi.com/1718-7729/29/8/413

Similar Items